An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Checked against the public recordLast updated Mar 22, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: Nivolumab; Drug: Dasatinib; Biological: Relatlimab; Biological: Ipilimumab; Drug: BMS-986205
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Advanced Non Small Cell Lung Cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1 * Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment * Must have at least 1 lesion with measurable disease Exclusion Criteria: * Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment * Subjects who need daily oxygen therapy * People with autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope National Medical CenterDuarte, California
- University of Southern California (USC)Los Angeles, California
- Cedars-Sinai Medical CenterLos Angeles, California
- University of Californa, Los Angeles (UCLA)Los Angeles, California
- Hoag Memorial Hospital PresbyterianNewport Beach, California
- University of California San DiegoSan Diego, California
- University of Colorado DenverAurora, Colorado
- Yale Cancer CenterNew Haven, Connecticut
- University of Kansas Cancer CenterWestwood, Kansas
- University of Maryland - Marlene and Stewart Greenebaum Cancer CenterBaltimore, Maryland
- Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
- Massachusetts General HospitalBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 22, 2021. Always confirm current availability with the study team.